264 related articles for article (PubMed ID: 24389431)
1. Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression.
Guin S; Ru Y; Wynes MW; Mishra R; Lu X; Owens C; Barn AE; Vasu VT; Hirsch FR; Kern JA; Theodorescu D
J Thorac Oncol; 2013 Dec; 8(12):1492-501. PubMed ID: 24389431
[TBL] [Abstract][Full Text] [Related]
2. KRAS oncogene substitutions in Korean NSCLC patients: clinical implication and relationship with pAKT and RalGTPases expression.
Kim EY; Kim A; Kim SK; Kim HJ; Chang J; Ahn CM; Lee JS; Shim HS; Chang YS
Lung Cancer; 2014 Aug; 85(2):299-305. PubMed ID: 24863005
[TBL] [Abstract][Full Text] [Related]
3. New syngeneic inflammatory-related lung cancer metastatic model harboring double KRAS/WWOX alterations.
Bleau AM; Freire J; Pajares MJ; Zudaire I; Anton I; Nistal-Villán E; Redrado M; Zandueta CN; Garmendia I; Ajona D; Blanco D; Pio R; Lecanda F; Calvo A; Montuenga LM
Int J Cancer; 2014 Dec; 135(11):2516-27. PubMed ID: 24473991
[TBL] [Abstract][Full Text] [Related]
4. The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer.
Guin S; Theodorescu D
Acta Pharmacol Sin; 2015 Mar; 36(3):291-7. PubMed ID: 25557115
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
[TBL] [Abstract][Full Text] [Related]
6. Differential involvement of RalA and RalB in colorectal cancer.
Martin TD; Der CJ
Small GTPases; 2012; 3(2):126-30. PubMed ID: 22790202
[TBL] [Abstract][Full Text] [Related]
7. Genetic deletion of RALA and RALB small GTPases reveals redundant functions in development and tumorigenesis.
Peschard P; McCarthy A; Leblanc-Dominguez V; Yeo M; Guichard S; Stamp G; Marshall CJ
Curr Biol; 2012 Nov; 22(21):2063-8. PubMed ID: 23063435
[TBL] [Abstract][Full Text] [Related]
8. An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.
Seguin L; Kato S; Franovic A; Camargo MF; Lesperance J; Elliott KC; Yebra M; Mielgo A; Lowy AM; Husain H; Cascone T; Diao L; Wang J; Wistuba II; Heymach JV; Lippman SM; Desgrosellier JS; Anand S; Weis SM; Cheresh DA
Nat Cell Biol; 2014 May; 16(5):457-68. PubMed ID: 24747441
[TBL] [Abstract][Full Text] [Related]
9. Activation of RAS family members confers resistance to ROS1 targeting drugs.
Cargnelutti M; Corso S; Pergolizzi M; Mévellec L; Aisner DL; Dziadziuszko R; Varella-Garcia M; Comoglio PM; Doebele RC; Vialard J; Giordano S
Oncotarget; 2015 Mar; 6(7):5182-94. PubMed ID: 25691052
[TBL] [Abstract][Full Text] [Related]
10. RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer.
Khawaja H; Campbell A; Roberts JZ; Javadi A; O'Reilly P; McArt D; Allen WL; Majkut J; Rehm M; Bardelli A; Di Nicolantonio F; Scott CJ; Kennedy R; Vitale N; Harrison T; Sansom OJ; Longley DB; Evergren E; Van Schaeybroeck S
Cell Death Dis; 2020 Oct; 11(10):930. PubMed ID: 33122623
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of RalA signaling pathway in treatment of non-small cell lung cancer.
Male H; Patel V; Jacob MA; Borrego-Diaz E; Wang K; Young DA; Wise AL; Huang C; Van Veldhuizen P; O'Brien-Ladner A; Williamson SK; Taylor SA; Tawfik O; Esfandyari T; Farassati F
Lung Cancer; 2012 Aug; 77(2):252-9. PubMed ID: 22498113
[TBL] [Abstract][Full Text] [Related]
12. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
13. Activation and involvement of Ral GTPases in colorectal cancer.
Martin TD; Samuel JC; Routh ED; Der CJ; Yeh JJ
Cancer Res; 2011 Jan; 71(1):206-15. PubMed ID: 21199803
[TBL] [Abstract][Full Text] [Related]
14. RalA suppresses early stages of Ras-induced squamous cell carcinoma progression.
Sowalsky AG; Alt-Holland A; Shamis Y; Garlick JA; Feig LA
Oncogene; 2010 Jan; 29(1):45-55. PubMed ID: 19802010
[TBL] [Abstract][Full Text] [Related]
15. Effects of RAL signal transduction in KRAS- and BRAF-mutated cells and prognostic potential of the RAL signature in colorectal cancer.
Győrffy B; Stelniec-Klotz I; Sigler C; Kasack K; Redmer T; Qian Y; Schäfer R
Oncotarget; 2015 May; 6(15):13334-46. PubMed ID: 26033452
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of RalB is important for bladder cancer cell growth and metastasis.
Wang H; Owens C; Chandra N; Conaway MR; Brautigan DL; Theodorescu D
Cancer Res; 2010 Nov; 70(21):8760-9. PubMed ID: 20940393
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues.
Liang H; Zhang J; Shao C; Zhao L; Xu W; Sutherland LC; Wang K
J Exp Clin Cancer Res; 2012 Apr; 31(1):36. PubMed ID: 22537942
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.
Sunaga N; Shames DS; Girard L; Peyton M; Larsen JE; Imai H; Soh J; Sato M; Yanagitani N; Kaira K; Xie Y; Gazdar AF; Mori M; Minna JD
Mol Cancer Ther; 2011 Feb; 10(2):336-46. PubMed ID: 21306997
[TBL] [Abstract][Full Text] [Related]
19. WT1 enhances proliferation and impedes apoptosis in KRAS mutant NSCLC via targeting cMyc.
Wu C; Wang S; Xu C; Tyler A; Li X; Andersson C; Oji Y; Sugiyama H; Chen Y; Li A
Cell Physiol Biochem; 2015; 35(2):647-62. PubMed ID: 25613309
[TBL] [Abstract][Full Text] [Related]
20. Expression of ral GTPases, their effectors, and activators in human bladder cancer.
Smith SC; Oxford G; Baras AS; Owens C; Havaleshko D; Brautigan DL; Safo MK; Theodorescu D
Clin Cancer Res; 2007 Jul; 13(13):3803-13. PubMed ID: 17606711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
